Imagen de Portada

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

Guardado en:
Publicado en:NPJ Breast Cancer vol. 10, no. 1 (2024), p. 26
Autor principal: Tarantino, Paolo
Otros Autores: Leone, Julieta, Vallejo, Carlos T., Freedman, Rachel A., Waks, Adrienne G., Martínez-Sáez, Olga, Garrido-Castro, Ana, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose P.
Publicado:
Nature Publishing Group
Materias:
Patients
Marital status
Histology
Population-based studies
Medical prognosis
Mastectomy
Cancer therapies
Medical research
Oncology
Tumors
Metropolitan areas
Chemotherapy
Breast cancer
Clinical outcomes
Acceso en línea:Citation/Abstract
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).
ISSN:2374-4677
DOI:10.1038/s41523-024-00634-6
Fuente:Health & Medical Collection